Oxidative Medicine and Cellular Longevity
Volume 2019 (2019), Article ID 8743257, 10 pages
https://doi.org/10.1155/2019/8743257

Review Article

Mitochondrial F-ATP Synthase and Its Transition into an Energy-Dissipating Molecular Machine

Giovanna Lippe, Gabriele Coluccino, Marco Zancani, Walter Baratta, and Paola Crusiz

Department of Agricultural, Food, Environmental and Animal Sciences, University of Udine, Italy

Correspondence should be addressed to Giovanna Lippe; giovanna.lippe@uniud.it

Received 25 January 2019; Accepted 18 March 2019; Published 15 April 2019

Guest Editor: Ulrike Hendgen-Cotta

Copyright © 2019 Giovanna Lippe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

The mitochondrial F-ATP synthase is the principal energy-conserving nanomotor of cells that harnesses the proton motive force generated by the respiratory chain to make ATP from ADP and phosphate in a process known as oxidative phosphorylation. In the energy-converting membranes, F-ATP synthase is a multisubunit complex organized into a membrane-extrinsic F₁ sector and a membrane-intrinsic FO domain, linked by central and peripheral stalks. Due to its essential role in the cellular metabolism, malfunction of F-ATP synthase has been associated with a variety of pathological conditions, and the enzyme is now considered as a promising drug target for multiple disease conditions and for the regulation of energy metabolism. We discuss structural and functional features of mitochondrial F-ATP synthase as well as several conditions that partially or fully inhibit the coupling between the F₁ catalytic activities and the FO proton translocation, thus decreasing the cellular metabolic efficiency and transforming the enzyme into an energy-dissipating structure through molecular mechanisms that still remain to be defined.

1. Introduction

Mitochondria are highly dynamic enclosed organelles harbouring an outer membrane (OMM) and an inner membrane (IMM) with a small intermembrane space separating them. The surface of the IMM is significantly bigger than that of the OMM due to the presence of numerous invaginations called cristae that extend more or less deeply into the protein-dense central matrix [1]. In differentiated aerobic cells, mitochondria are crucial for ATP production from nutrient oxidation; for ROS (reactive oxygen species) production, which contributes to mitochondrial damage in several pathologies and to redox signalling from the organelle to the rest of the cell [2, 3]; for intracellular calcium signalling; and for execution of cell death among other functions [4]. This functional versatility is matched by their great variability in number and structure depending on the tissue and the developmental stage. Mitochondria interact with the cytoskeleton, which modulates their subcellular localization and motility, and with the endoplasmic reticulum for calcium homeostasis. ATP is produced from ADP and phosphate (Pi) by the F-type ATP synthase complex (or complex V) in a process known as oxidative phosphorylation, which takes place in the IMM. The four complexes of the respiratory chain carry out a series of redox reactions, resulting in oxygen reduction to water, which are able to sustain the proton-pumping activity of complexes I, III, and IV. These latter generate an electrochemical gradient across the IMM known as proton motive force, which is absolutely necessary for F-ATP synthase to produce ATP [5]. From the intermembrane space, however, protons may leak back to the mitochondrial matrix independent of ATP synthesis, decreasing the metabolic efficiency and giving rise to mitochondrial uncoupling. In the last decade, there has been a growing interest in characterizing the endogenous dissipating pathways, as well as in the chemical agents able to induce a mild mitochondrial uncoupling, which may provide a powerful therapeutic treatment for widespread diseases such as obesity and diabetes [6, 7]. This review is especially dedicated to F-ATP synthase and its transition into an energy-dissipating enzyme through molecular mechanisms that still remain to be defined.

2. F-Type ATP Synthase as a Molecular Motor

The complex structure and the unique functional mechanism of F-ATP synthase are now known thanks to more than 50 years of studies by several researchers, including the three scientists that were awarded the Nobel Prize: Sir Peter Mitchell, who demonstrated that F-ATP synthase relies on the electrochemical gradient to perform catalysis [5]; Sir John E. Walker, who solved the mammalian F-ATP synthase structure [8]; and Paul Boyer, who clarified the mechanism of rotational catalysis [9]. Nevertheless, some aspects of the coupling mechanism between proton translocation and catalysis remain to be fully understood [10].

In all energy-converting membranes, F-ATP synthase consists of a roughly globular, water-soluble F₁ head and a membrane-embedded FO subcomplex comprising the a subunit and a ring of multiple c subunits. These moieties are connected by two stalks: the lateral or peripheral stalk, which is structurally part of the FO moiety, and the central stalk, which is associated to the F₁ sector [10]. All types of F-ATP synthases function as nanometer-scale rotary machines consisting of two motors linked by a rotor, which comprises the c-ring and the central stalk. One motor located in the FO sector generates movement of the rotor at a rate of ~100 revolutions/s by consuming the proton motive force; the other, located in the F₁ moiety, uses energy transmitted by the rotor to synthesize ATP. The synthetic motor can work in reverse, driving the rotor backward with energy from ATP, releasing ADP and phosphate, and generating a membrane potential [1]. The strict correlation between proton flux and rotor rotation has been confirmed by measurement of the H⁺ : ATP ratio in a bacterial F-ATP synthase, where a “perfect chemomechanical coupling” between proton translocation, rotary motion, and ATP synthesis/hydrolysis has been reported, excluding “slip” of the rotor, i.e., rotation of the c-ring without carrying a proton [11]. This coupling is instead disrupted by the antibiotic oligomycin, which binds the c-ring, preventing it to rotate in either directions [12]. Our understanding of how the enzyme works has greatly come from single-molecule studies, which allowed direct visualization by fluorescence microscopy of rotating bacterial F-ATP synthases driven by ATP hydrolysis [13] and, more recently, from electron cryomicroscopy analysis of mitochondrial and bacterial ATP synthases, revealing the architecture of the FO sector and thus the mechanisms of proton translocation [14].

In its simplest bacterial form, the FO sector consists of 9-15 copies of the subunit c, two copies of the subunit b, and a copy of the subunit a [14]. While the b subunits constitute part of the peripheral stalk [15], the subunit a is embedded in the membrane, where it is organized into a four-helix horizontal bundle that wraps around the c-ring, forming two semichannels through which the H⁺ flow by protonation/deprotonation of conserved carboxylic residues present in each c subunit [16–18]. The eukaryotic FO sector is made up of subunits A6L, e, f, and g and 2 or 3 other additional subunits (DAPIT and 6.8PL in vertebrates; i/j, k, and l in yeast), besides subunits a, b, and c [14]. The smaller c-ring, which comprises 8 or 10 c subunits in metazoans and yeast, lowers the bioenergetic cost of ATP synthesis, i.e., the H⁺/ATP stoichiometry from 3.3 to 2.7, respectively [19].

The peripheral stalk tends to diverge throughout evolution, even though the overall structure seems to be constant [15]. The bacterial peripheral stalk consists of the b₂ dimer, which spans the whole enzyme, and a single copy of the subunit δ. Like the FO membrane-embedded part, the eukaryotic peripheral stalk is more complex. Its membrane distal part is constituted by one copy of the subunits b, F6, d, and OSCP (oligomycin-sensitivity conferral protein, homologous to the bacterial δ subunit) [20], while its base comprises the C-terminal region of subunit A6L [18, 21], the N-terminal domain of the subunit f [18], and the subunit i/j in yeast [22].

F₁ is the catalytic sector, which is always composed of three αβ dimers that alternate in surrounding the central stalk. The latter comprises the γ subunit, which is associated with the subunit ε in bacteria and with the subunits δ and ε in eukaryotes [10] (Figure 1). Indeed, the bacterial ε subunit is homologous to the mitochondrial δ subunit, whereas the mitochondrial ε subunit has no equivalent in the bacterial enzyme [10]. The catalytic nucleotide binding sites are located in the three β subunits at the interfaces with the respective three α subunits. According to Boyer’s catalysis model, subunit γ rotation within α₃β₃ takes each of the three β subunits through three major functional conformations, denoted βE (empty), βDP (bound to ADP), and βTP (bound to ATP), thereby synthesizing three Mg²⁺-ATP molecules during each 360° rotation. During ATP hydrolysis, the transition between βE, βTP, and βDP states drives the opposite rotation of the γ subunit and the c-ring, thereby causing the formation of a proton gradient. In both ATP synthetic and hydrolytic directions, Mg²⁺ is essential for catalysis [10].

Figure 1: Structure of the mitochondrial F-ATP synthase. Subunits are shown in colors as follows. F₁ is shown with the alternating α (green) and β subunits (red). On the left, the peripheral stalk (PS) includes the OSCP (yellow), b (dark blue), F6 (orange), and d (pink) subunits. The central stalk (CS) connecting the α₃β₃ subcomplex to the c-ring composed of 8 identical subunit c (purple) includes the γ (cyan), δ (blue), and ε (ice blue) subunits. The FO membrane sector includes the subunits a (dark red, mostly covered in the picture by other subunits), f (white), A6L (emerald, mostly covered by other subunits), g (light orange), and e (silver). In the membrane region, which is delineated by dotted lines, the subunits e and g, with the N-terminal part of subunit b, create a subdomain that bends the inner mitochondrial membrane.

Due to its complexity, the F-ATP synthase assembly occurs in a modular fashion to prevent formation of intermediates that could depolarize the membrane or waste ATP [23], although the pathways are still debated [24]. The structural and functional coupling between FO and F₁ in the mature complex is mainly guaranteed by the OSCP or δ subunit in mitochondria and in bacteria, respectively. Through its contacts with both the α₃β₃ hexamer and the peripheral stalk, OSCP or δ prevents corotation of the αβ dimers with the γ subunit, thereby ensuring very high enzyme efficiency [25]. Another domain crucial for the functional coupling is located at the C-terminus of β subunit, which is in direct contact with γ subunit, termed the DELSEED loop, which is thought to transfer the torque to γ from the nucleotide binding domain [26]. Moreover, in mitochondria, the high catalytic efficiency of F-ATP synthase seems to be mediated also by formation of the V-shaped dimers [27, 28]. The electron cryomicroscopy maps of the mammalian [29] and yeast [18] enzymes revealed that subunits e and g, with the N-terminal part of subunit b and probably of subunit k in yeast, create in the F-ATP synthase monomers a subdomain that bends the IMM. These bends would drive self-assembly of the monomers into V-shaped dimers. Then, dimers self-assemble into long rows of oligomers localized at the cristae ridges [30] to maintain the typical IMM morphology [31]. The mitochondrial cristae would act as proton traps, favouring effective ATP synthesis by F-ATP synthase localized at the apex. Electron cryotomography showed that the dimers are organized in situ with the peripheral stalks turned away from one another [32] and are formed through the contribution of several FO subunits (a, b, e, f, g, i/j, and k) [18].

3. Mitochondrial Uncoupling

Mitochondrial uncoupling is quite a general term and refers to any pathway that enables proton reentry into the matrix independent of ATP production. Indeed, the oxidative phosphorylation involves the coupling of redox reactions of the respiratory chain to ATP synthesis by the F-ATP synthase through a proton cycle across the IMM. These reactions, however, are not fully coupled, since protons can return to the mitochondrial matrix independent of ATP synthesis by either unregulated endogenous pathways, termed basal proton leaks, which are indeed modifiable by drugs or by inducible leaks through protein complexes (Figure 2). This energy-dissipating cycling occurs in all eukaryotic cells and accounts for a varying proportion of cellular metabolism, depending on the tissue type [33].

Figure 2: The proton circuit across the inner mitochondrial membrane. During the oxidative phosphorylation, the redox reactions of the four respiratory chain complexes are indirectly coupled to ATP synthesis by the F-ATP synthase dimers through the electrochemical proton gradient across the IMM. Return of protons into the matrix independent of ATP synthesis through the basal leak pathway, or through inducible leaks, decreases the electrochemical proton gradient and leads to mitochondrial uncoupling protecting mitochondria against ROS production. Proton back-leaks through the FO sector of F-ATP synthase, independent of the synthesis of ATP, lead to dissipation of the proton gradient, thus transforming F-ATP synthase into an energy-dissipating structure. Red arrows correspond to proton leaks.

Physiological uncoupling is typically mediated in mammals by the finely regulated uncoupling protein 1 (UCP1), an integral membrane protein of the brown adipose tissue (BAT) that mediates the leak of protons across the IMM, dissipating the proton gradient and inducing heat production [34]. Physiological uncoupling also enables fine-tuning of insulin secretion by uncoupling protein 2 (UCP2) in pancreatic β cells [35] and regulation of fatty acid metabolism by uncoupling protein 3 (UCP3), which is specific to skeletal muscle, BAT, and heart, although UCP2 and UCP3 functions are not clearly established [33]. Moreover, multiple ATP-dependent dissipative pathways exist in yeast mitochondria that include both selective [36, 37] and unselective channels [38]. In plants, besides UCPs [39], a further energy dissipation system has been described, called alternative oxidase (AOX), which couples ubiquinol oxidation with direct reduction of oxygen to water [40].

Mitochondrial uncoupling can also be induced by chemical uncouplers, i.e., small molecules that lessen the proton motive force across the IMM. These molecules belong to one of two general classes: protonophore uncouplers and nonprotonophores. Protonophore uncouplers, such as carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), are lipophilic weak acids able to traverse the membrane as an uncharged form, inducing complete uncoupling at very low concentration, i.e., in the nM range, and causing sudden increases of the respiratory rates that are oligomycin-insensitive [41]. Nonprotonophores can instead activate latent proton leaks to variable degrees through specific protein complexes that lead to mitochondrial dysfunction. Mitochondrial uncoupling can be measured directly as a decrease in the electrochemical gradient or indirectly, as a decrease in the phosphorylation efficiency, i.e., ADP/O stoichiometry, or/and as a decrease of the respiratory control ratio (RCR), i.e., the ratio between oxygen consumption during (state 3) and after (state 4) ADP phosphorylation.

Mitochondrial uncoupling is not completely harmful. Indeed, there is a close inverse relationship between increasing the proton leak and ROS generation in isolated mitochondria [42]. It is long known that addition to isolated mitochondria of uncouplers, as well as ADP, increases the oxygen consumption and lowers the mitochondrial electrochemical gradient, decreasing ROS production [43]. Conversely, inhibition of the ATP synthase capacity leads to accumulation of the electrons in the upstream complexes of the respiratory chain, promoting oxidative stress and mitochondrial dysfunction [3], as recently observed in diabetic cardiomyopathy in mice [44]. These observations support a role for endogenous mitochondrial uncoupling in protection against ROS production [2, 33]. Consistently, therapeutic mitochondrial uncoupling is reported to be protective in a variety of disorders, including obesity [45, 46], diabetes [47, 48], ischemia/reperfusion injury [33, 49], Parkinson’s disease [50], and aging [51], although the responsible factor(s) remain to be fully understood. Mild uncoupling can be obtained in different ways, i.e., by UCP activation, such as in obese diabetic mice, where UCP2 overexpression restored the impaired endothelium-dependent relaxation [48], or by the use of chemical uncouplers, such as niclosamide ethanolamine, which improved diabetic symptoms in mice [47], or the novel mitochondrial uncoupler BAM15, which has no off-target activity on other cellular membranes [52, 53]. Nevertheless, caution is always required when targeting mitochondrial uncoupling via lipophilic weak acids, even when they are selective, since, differently from the UCPs, their activity lacks autoregulation, i.e., is not desensitized by reduction of the membrane potential [7].

4. F-ATP Synthase Uncoupling

The term F-ATP synthase uncoupling refers to any condition that inhibits the coupling between the F₁ catalytic activities and the proton translocation by FO. Conditions that activate the formation of a proton back-leak through FO independently from the synthesis of ATP lead to dissipation of the proton gradient, thus transforming F-ATP synthase into an energy-dissipating enzyme. Indeed, the enzyme appears to have an intrinsic robustness, as recently demonstrated by the formation of stable incomplete subcomplexes after disruption of individual human genes for subunits in the FO membrane portion [24]. However, the dissipative pathways and their modulation are still to be defined in the majority of cases. For example, mammalian mitochondrial oxidation of mono- and dithiols located in FO induces a complete uncoupling of ATP synthase, which is not reverted by oligomycin [54]. The authors proposed that the lesion was on the cytosolic side of the oligomycin block point of the proton channel, a location that would suggest the involvement of the unique conserved cysteine residue of the subunit c. Moreover, the formation of a disulphide bridge between two vicinal subunits b of two adjacent F-ATP synthase monomers induces a severe oligomycin-insensitive uncoupling, of which the molecular mechanism has not been fully elucidated [55]. Another latent oligomycin-insensitive proton-translocating pathway in FO would comprise the subunits e, f, g, and A6L, of which conductance was markedly increased upon displacement of the matrix protein factor B from FO. This effect is due to oxidation of vicinal thiols of factor B and is parallel to mitochondrial uncoupling [56, 57]. More recently, the matrix protein Bcl-XL has been identified in neurons as able to revert ATP synthase uncoupling by binding to the β subunit, although the underlying mechanism remains to be established [58, 59]. Interestingly, the leucine-rich pentatricopeptide repeat containing protein (Lrpprc), a key posttranscriptional regulator of mtDNA expression defective in the French Canadian type of Leigh syndrome, has also resulted to be crucial for F-ATP synthase coupling by modulating the proper assembly of the subunits OSCP and A6L. In the Lrpprc conditional knockout mouse heart, decrease in ATP production is due to the appearance of uncoupled subassembled F-ATP synthase complexes, causing hyperpolarization and increase of mitochondrial ROS production, in spite of an unaltered ADP/O ratio, thus showing the consequences of F-ATP synthase assembly defects on mitochondrial bioenergetics [60].

F-ATP synthase uncoupling is also stimulated by a number of cationic dyes, namely, coriphosphine, Nile blue, pyronin Y, and acridine orange, which increase both state 4 respiration and ATPase activity, but the binding sites remain to be established [61]. Another molecule able to stimulate a proton back-leak through the eukaryotic FO is 17β-estradiol that, at micromolar concentrations, induces an “intrinsically slipping state” of F-ATP synthase, while the enzyme is actually catalysing ATP synthesis, therefore resulting in a depressed RCR and ADP/O ratio [62]. Such partially uncoupled state is promoted by ATP and reversed by oligomycin, but not by resveratrol, supporting the fact that the FO moiety is a site of action of 17β-estradiol. Possibly, a conformational change is transmitted to FO through the OSCP subunit, which contains a binding site for 17β-estradiol able to mediate the inhibition of ATPase activity both at nanomolar and micromolar concentrations [63, 64]. The ability of ATP to cause enzyme uncoupling seems conserved, since a transition from a tightly coupled to a loosely coupled state triggered by ATP binding is also described for bacterial ATP synthase, although the underlying mechanism remains to be elucidated [65, 66]. A complete uncoupling is instead induced by addition of Ca²⁺, which, differently from Mg²⁺, only sustains ATP hydrolysis by F₁ that is not coupled to generation of a proton gradient in both prokaryotes [67] and eukaryotes [68–70], in spite of Ca²⁺ ability to sustain the F₁ rotational catalysis [71]. These data strongly suggest that the catalytic site has a different conformation state when occupied by Ca²⁺ that, when compared with Mg²⁺, is unable to couple the chemical catalysis to the generation of a proton gradient.

Based on these observations, it has been suggested that Ca²⁺ binding, possibly by replacing Mg²⁺ at the catalytic site [72], together with ROS could cause a drastic conformational change to the ATP synthase dimer. This would give rise to the formation of a high conductance channel, named permeability transition pore (PTP), thus representing an extreme form of enzyme uncoupling. The PTP is a nonselective channel modulated by Ca²⁺ and ROS and is located in the IMM, and its opening implies the dissipation of the proton gradient with cessation of ATP synthesis and maximization of ATP hydrolysis. The PTP displays a range of conductance states, which have been originally characterized by electrophysiology in mammals [73]. Persistent PTP opening causes equilibration of low-molecular-weight (<1500 Da) molecules across the IMM, which disrupts any metabolic gradient, followed by an osmotic stress leading to matrix swelling and, eventually, to OMM rupture and release of proapoptotic factors like cytochrome c, endonuclease G, and AIF. Indeed, the PTP is causally involved in cell death in several diseases, and the most documented cases include heart ischemia, muscular dystrophies, and neurodegenerative diseases [74].

The involvement of F-ATP synthase in PTP formation has been supported by (i) genetic manipulation of selected enzyme subunits whose ablation affected the PTP function [75, 76]; (ii) electrophysiological measurements, which showed that the PTP generated by F-ATP synthase is characterized by a variety of conductances similar to those of the native pore [77, 78]; and (iii) mutagenesis of specific residues of F-ATP synthase within F₁ [72] or FO [79–81]. In particular, OSCP, located on top of F-ATP synthase, appears ideally suited to transmit Ca²⁺-dependent conformational changes from F₁ to the rigid peripheral stalk causing pore formation within the F-ATP synthase membrane portion, probably at the interface between the two monomers forming an F-ATP synthase dimer. Indeed, this model is strongly supported by the observations that OSCP (i) is the binding site of cyclophilin (CyP) D, the best characterized PTP inducer, which sensitizes the PTP to the effects of matrix Ca²⁺ and is released by cyclosporin A resulting in PTP inhibition [77, 82]; (ii) is the binding site of the immunomodulatory drug benzodiazepine (Bz) 423 [83], which like CyPD acts as a PTP inducer [77]; (iii) contains a highly conserved histidyl residue (H112 in the human mature protein) responsible for the inhibitory effect of acidic matrix pH on the PTP [81]; (iv) undergoes, in contrast to major subunits of the ATP synthase complex, a selective decrease of its expression level, which is concomitant with CyPD upregulation and PTP activation in brain mitochondria from aging mice [84]; and (v) interacts with the β amyloid protein in cultured neurons, leading to PTP sensitization, and in the brain of individuals with Alzheimer’s disease, potentially mediating mitochondrial impairment [85]. Nevertheless, the Ca²⁺- and ROS-dependent long-range conformational changes that could be responsible for the PTP formation in the FO sector remain to be defined. Moreover, other models of PTP have been advanced that hypothesize the PTP resides in the c-ring of ATP synthase [76, 79] or, alternatively, in some other mitochondrial components not involving ATP synthase [86] so that its molecular nature is still a matter of debate [25].

5. F-ATP Synthase as a Target for Drug Development

Until now, malfunction of F-ATP synthase has been associated with a variety of pathological conditions, such as cardiovascular [87] and neurodegenerative diseases [88], obesity and type 2 diabetes [89, 90], and cancer [91]. Despite such important evidence, F-ATP synthase has only recently been used as an effective drug target for disease conditions and for the regulation of energy metabolism [92], despite the fact that more than 300 natural and synthetic molecules are known to bind and inhibit this complex [93]. Moreover, the recent finding that F-ATP synthase is involved in PTP formation may make this complex a viable target for future therapy in a variety of diseases [25]. Selective interaction of F-ATP synthase with some drugs has been identified. For example, the enzyme is recognized as a molecular target of the cytotoxic agent apoptolidin, which induces apoptosis in human cancer cell lines by binding to the FO subunit a and inhibiting the enzyme activity [94]. Another example is provided by the immunomodulatory drug Bz 423, which activates the mitochondrial pathway of apoptosis selectively in pathogenic lymphocytes [83]. More recently, the α subunit of the F₁ sector has been recognized as a target for the drug candidate J147, which shows therapeutic efficacy in several mouse models of Alzheimer’s disease. By targeting ATP synthase, J147 causes an increase in intracellular Ca²⁺ leading to activation of the AMPK/mTOR pathway, a canonical longevity mechanism [95]. Moreover, the enzyme is a very promising molecular target for the development of new antimicrobial agents that selectively inhibit the bacterial F-ATP synthases, such as bedaquiline that represents the first compound of a new class of potent antituberculosis drugs [96]. Attention has recently focused on dietary phytochemicals with antimicrobial properties, a variety of which inhibits the bacterial F-ATP synthase to a variable degree depending on the type and positioning of the functional groups. Both F₁ and FO subunits have been identified as contributing to the binding sites for such inhibitors [92]. Because dietary phytochemicals also inhibit the mitochondrial F-ATP synthase [97], attempts are being made to modify the functional groups of these compounds, making them more potent and selective inhibitors of the bacterial ATP synthases [92]. On the other hand, many of these phytochemicals exhibit diverse activities, such as antioxidant, anticancerogenic, and antiobesity actions [97]. An example is resveratrol, a well-characterized inhibitor of the mitochondrial F-ATP synthase whose binding site is located between the C-terminal part of the γ subunit and the βTP subunit [98]. Resveratrol also increases the basal energy expenditure and thermogenesis, along with alteration of numerous signalling pathways that converge on the mitochondria [99].

Recently, there has been an increased interest in the use of essential oils (EOs) as preventive and therapeutic agents for treatment of various diseases, including obesity [100]. EOs are secondary metabolites of plants representing a mixture of a variety of volatile molecules such as terpenoids and phenol-derived aromatic and aliphatic components. EOs also possess antimicrobial, anti-inflammatory, anticancer, and antioxidant properties, but the molecular targets are still to be defined in the majority of cases [101]. The EO component D-limonene, which is recognized as a potential chemotherapeutic agent [102], induces apoptosis via the mitochondrial pathway in several human cell lines [103] and has also antiobesity activity, mainly by induction of the brown fat-like phenotype in white adipocytes [104]. Interestingly, the EO component p-cymene directly induces a mild uncoupling of F-ATP synthase, leading to an ATP-stimulated, oligomycin-sensitive proton leak through the FO moiety that decreases the electrochemical gradient and the respiratory control ratio but not the ADP/O ratio [105]. Such properties might suggest its use as a pharmacological agent to decrease the metabolic efficiency. However, caution is required, because affecting all mitochondria throughout the body may be a high-risk treatment, as energy homeostasis may be compromised in tissues such as the heart and brain.

6. Conclusions

The existence of several conditions that inhibit or abolish the coupling between F₁ and FO clearly indicates that the energy-conserving enzyme can transform into an energy-dissipating structure within the IMM. Available structures of the fully coupled F-ATP synthase do not display obvious features that can accommodate these dissipative pathways. Indeed, the molecular definition of the pathways responsible for F-ATP synthase uncoupling and of its potential regulators still represents a research challenge in bioenergetics. Due to the central role of F-ATP synthase in cellular metabolism, this definition is crucial and potentially useful for therapy in a variety of diseases.

Conflicts of Interest

The authors declare that they have no conflicts of interest related to this work.

Acknowledgments

We thank Federico Fogolari (University of Udine) for his help with the figure of F-ATP synthase.

References

W. Junge, H. Sielaff, and S. Engelbrecht, “Torque generation and elastic power transmission in the rotary FoF₁-ATPase,” Nature, vol. 459, no. 7245, pp. 364–370, 2009.

M. P. Murphy, “How mitochondria produce reactive oxygen species,” Biochemical Journal, vol. 417, no. 1, pp. 1–13, 2009.

N. Kaludercic and V. Giorgio, “The dual function of reactive oxygen/nitrogen species in bioenergetics and cell death: the role of ATP synthase,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3869610, 17 pages, 2016.

C. Mammucari, A. Raffaello, D. Vecellio Reane, G. Gherardi, A. de Mario, and R. Rizzuto, “Mitochondrial calcium uptake in organ physiology: from molecular mechanism to animal models,” Pflügers Archiv - European Journal of Physiology, vol. 470, no. 8, pp. 1165–1179, 2018.

P. Mitchell, “Keilin’s respiratory chain concept and its chemiosmotic consequences,” Science, vol. 206, no. 4423, pp. 1148–1159, 1979.

M. Liesa and O. S. Shirihai, “Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure,” Cell Metabolism, vol. 17, no. 4, pp. 491–506, 2013.

M. Jastroch, S. Keipert, and F. Perocchi, “From explosives to physiological combustion: next generation chemical uncouplers,” Molecular Metabolism, vol. 3, no. 2, pp. 86-87, 2014.

J. P. Abrahams, A. G. W. Leslie, R. Lutter, and J. E. Walker, “Structure at 2.8 Â resolution of F₁-ATPase from bovine heart mitochondria,” Nature, vol. 370, no. 6491, pp. 621–628, 1994.

P. D. Boyer, “The ATP synthase—a splendid molecular machine,” Annual Review of Biochemistry, vol. 66, no. 1, pp. 717–749, 1997.

J. E. Walker, “The ATP synthase: the understood, the uncertain and the unknown,” Biochemical Society Transactions, vol. 41, no. 1, pp. 1–16, 2013.

N. Soga, K. Kimura, K. Kinosita Jr, M. Yoshida, and T. Suzuki, “Perfect chemomechanical coupling of FoF₁-ATP synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 114, no. 19, pp. 4960–4965, 2017.

J. Symersky, D. Osowski, D. E. Walters, and D. M. Mueller, “Oligomycin frames a common drug-binding site in the ATP synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 35, pp. 13961–13965, 2012.

M. Futai, M. Nakanishi-Matsui, H. Okamoto, M. Sekiya, and R. K. Nakamoto, “Rotational catalysis in proton pumping ATPases: from E. coli F-ATPase to mammalian V-ATPase,” Biochimica et Biophysica Acta (BBA) – Bioenergetics, vol. 1817, no. 10, pp. 1711–1721, 2012.

H. Guo and J. L. Rubinstein, “Cryo-EM of ATP synthases,” Current Opinion in Structural Biology, vol. 52, pp. 71–79, 2018.

L. Colina-Tenorio, A. Dautant, H. Miranda-Astudillo, M. F. Giraud, and D. González-Halphen, “The peripheral stalk of rotary ATPases,” Frontiers in Physiology, vol. 9, p. 1243, 2018.

E. Morales-Rios, M. G. Montgomery, A. G. W. Leslie, and J. E. Walker, “Structure of ATP synthase from Paracoccus denitrificans determined by X-ray crystallography at 4.0 Å resolution,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 43, pp. 13231–13236, 2015.

M. Allegretti, N. Klusch, D. J. Mills, J. Vonck, W. Kühlbrandt, and K. M. Davies, “Horizontal membrane-intrinsic α-helices in the stator a-subunit of an F-type ATP synthase,” Nature, vol. 521, no. 7551, pp. 237–240, 2015.

H. Guo, S. A. Bueler, and J. L. Rubinstein, “Atomic model for the dimeric FO region of mitochondrial ATP synthase,” Science, vol. 358, no. 6365, pp. 936–940, 2017.

I. N. Watt, M. G. Montgomery, M. J. Runswick, A. G. W. Leslie, and J. E. Walker, “Bioenergetic cost of making an adenosine triphosphate molecule in animal mitochondria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 39, pp. 16823–16827, 2010.

D. M. Rees, A. G. W. Leslie, and J. E. Walker, “The structure of the membrane extrinsic region of bovine ATP synthase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 51, pp. 21597–21601, 2009.

J. Lee, S. J. Ding, T. B. Walpole et al., “Organization of subunits in the membrane domain of the bovine F-ATPase revealed by covalent cross-linking,” Journal of Biological Chemistry, vol. 290, no. 21, pp. 13308–13320, 2015.

A. P. Srivastava, M. Luo, W. Zhou et al., “High-resolution cryo-EM analysis of the yeast ATP synthase in a lipid membrane,” Science, vol. 360, no. 6389, article eaas9699, 2018.

T. Rühle and D. Leister, “Assembly of F₁F₀-ATP synthases,” Biochimica et Biophysica Acta (BBA) – Bioenergetics, vol. 1847, no. 9, pp. 849–860, 2015.

J. He, H. C. Ford, J. Carroll et al., “Assembly of the membrane domain of ATP synthase in human mitochondria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 115, no. 12, pp. 2988–2993, 2018.

V. Giorgio, F. Fogolari, G. Lippe, and P. Bernardi, “OSCP subunit of mitochondrial ATP synthase: role in regulation of enzyme function and of its transition to a pore,” British Journal of Pharmacology, 2018, In press.

M. Tanigawara, K. V. Tabata, Y. Ito et al., “Role of the DELSEED loop in torque transmission of F1-ATPase,” Biophysical Journal, vol. 103, no. 5, pp. 970–978, 2012.

M. Strauss, G. Hofhaus, R. R. Schröder, and W. Kühlbrandt, “Dimer ribbons of ATP synthase shape the inner mitochondrial membrane,” The EMBO Journal, vol. 27, no. 7, pp. 1154–1160, 2008.

E. Bisetto, P. Picotti, V. Giorgio, V. Alverdi, I. Mavelli, and G. Lippe, “Functional and stoichiometric analysis of subunit e in bovine heart mitochondrial F₀F₁ATP synthase,” Journal of Bioenergetics and Biomembranes, vol. 40, no. 4, pp. 257–267, 2008.

L. A. Baker, I. N. Watt, M. J. Runswick, J. E. Walker, and J. L. Rubinstein, “Arrangement of subunits in intact mammalian mitochondrial ATP synthase determined by cryo-EM,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 29, pp. 11675–11680, 2012.

C. Anselmi, K. M. Davies, and J. D. Faraldo-Gómez, “Mitochondrial ATP synthase dimers spontaneously associate due to a long-range membrane-induced force,” The Journal of general physiology, vol. 150, no. 5, pp. 763–770, 2018.

P. Paumard, J. Vaillier, B. Coulary et al., “The ATP synthase is involved in generating mitochondrial cristae morphology,” The EMBO Journal, vol. 21, no. 3, pp. 221–230, 2002.

K. M. Davies, M. Strauss, B. Daum et al., “Macromolecular organization of ATP synthase and complex I in whole mitochondria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 34, pp. 14121–14126, 2011.

S. Cadenas, “Mitochondrial uncoupling, ROS generation and cardioprotection,” Biochimica et Biophysica Acta (BBA) - Bioenergetics, vol. 1859, no. 9, pp. 940–950, 2018.

P. G. Crichton, Y. Lee, and E. R. S. Kunji, “The molecular features of uncoupling protein 1 support a conventional mitochondrial carrier-like mechanism,” Biochimie, vol. 134, pp. 35–50, 2017.

C. Affourtit, M. Jastroch, and M. D. Brand, “Uncoupling protein-2 attenuates glucose-stimulated insulin secretion in INS-1E insulinoma cells by lowering mitochondrial reactive oxygen species,” Free Radical Biology and Medicine, vol. 50, no. 5, pp. 609–616, 2011.

S. Prieto, F. Bouillaud, and E. Rial, “The mechanism for the ATP-induced uncoupling of respiration in mitochondria of the yeast Saccharomyces cerevisiae,” Biochemical Journal, vol. 307, no. 3, pp. 657–661, 1995.

S. Prieto, F. Bouillaud, and E. Rial, “The nature and regulation of the ATP-induced anion permeability in Saccharomyces cerevisiae mitochondria,” Archives of Biochemistry and Biophysics, vol. 334, no. 1, pp. 43–49, 1996.

S. Uribe-Carvajal, L. A. Luévano-Martínez, S. Guerrero-Castillo, A. Cabrera-Orefice, N. A. Corona-de-la-Peña, and M. Gutiérrez-Aguilar, “Mitochondrial unselective channels throughout the eukaryotic domain,” Mitochondrion, vol. 11, no. 3, pp. 382–390, 2011.

X. Pu, X. Lv, T. Tan, F. Fu, G. Qin, and H. Lin, “Roles of mitochondrial energy dissipation systems in plant development and acclimation to stress,” Annals of Botany, vol. 116, no. 4, pp. 583–600, 2015.

G. C. Vanlerberghe, G. D. Martyn, and K. Dahal, “Alternative oxidase: a respiratory electron transport chain pathway essential for maintaining photosynthetic performance during drought stress,” Physiologia Plantarum, vol. 157, no. 3, pp. 322–337, 2016.

H. Terada, “Uncouplers of oxidative phosphorylation,” Environmental Health Perspectives, vol. 87, pp. 213–218, 1990.

S. S. Korshunov, V. P. Skulachev, and A. A. Starkov, “High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria,” FEBS Letters, vol. 416, no. 1, pp. 15–18, 1997.

A. Boveris and B. Chance, “The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen,” Biochemical Journal, vol. 134, no. 3, pp. 707–716, 1973.

R. Ni, D. Zheng, S. Xiong et al., “Mitochondrial calpain-1 disrupts ATP synthase and induces superoxide generation in type-1 diabetic hearts: a novel mechanism contributing to diabetic cardiomyopathy,” Diabetes, vol. 65, no. 1, pp. 255–268, 2016.

R. A. Busiello, S. Savarese, and A. Lombardi, “Mitochondrial uncoupling proteins and energy metabolism,” Frontiers in Physiology, vol. 6, p. 36, 2015.

J. A. Harper, K. Dickinson, and M. D. Brand, “Mitochondrial uncoupling as a target for drug development for the treatment of obesity,” Obesity Reviews, vol. 2, no. 4, pp. 255–265, 2001.

H. Tao, Y. Zhang, X. Zeng, G. I. Shulman, and S. Jin, “Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice,” Nature Medicine, vol. 20, no. 11, pp. 1263–1269, 2014.

X. Y. Tian, W. T. Wong, A. Xu et al., “Uncoupling protein-2 protects endothelial function in diet-induced obese mice,” Circulation Research, vol. 110, no. 9, pp. 1211–1216, 2012.

C. Ozcan, M. Palmeri, T. L. Horvath, K. S. Russell, and R. R. Russell III, “Role of uncoupling protein 3 in ischemia-reperfusion injury, arrhythmias, and preconditioning,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 304, no. 9, pp. H1192–H1200, 2013.

R. Islam, L. Yang, M. Sah et al., “A neuroprotective role of the human uncoupling protein 2 (hUCP2) in a Drosophila Parkinson’s disease model,” Neurobiology of Disease, vol. 46, no. 1, pp. 137–146, 2012.

C. C. Caldeira da Silva, F. M. Cerqueira, L. F. Barbosa, M. H. G. Medeiros, and A. J. Kowaltowski, “Mild mitochondrial uncoupling in mice affects energy metabolism, redox balance and longevity,” Aging Cell, vol. 7, no. 4, pp. 552–560, 2008.

C. Koliaki and M. Roden, “Alterations of mitochondrial function and insulin sensitivity in human obesity and diabetes mellitus,” Annual Review of Nutrition, vol. 36, no. 1, pp. 337–367, 2016.

Y. Tai, L. Li, X. Peng et al., “Mitochondrial uncoupler BAM15 inhibits artery constriction and potently activates AMPK in vascular smooth muscle cells,” Acta Pharmaceutica Sinica B, vol. 8, no. 6, pp. 909–918, 2018.

T. Yagi and Y. Hatefi, “Thiols in oxidative phosphorylation: inhibition and energy-potentiated uncoupling by monothiol and dithiol modifiers,” Biochemistry, vol. 23, no. 11, pp. 2449–2455, 1984.

G. Lippe, F. Dabbeni Sala, and M. C. Sorgato, “ATP synthase complex from beef heart mitochondria. Role of the thiol group of the 25-kDa subunit of Fo in the coupling mechanism between Fo and F1,” Journal of Biological Chemistry, vol. 263, no. 35, pp. 18627–18634, 1988.

S. Joshi and J. B. Hughes, “Inhibition of coupling factor B activity by cadmium ion, arsenite-2,3-dimercaptopropanol, and phenylarsine oxide, and preferential reactivation by dithiols,” Journal of Biological Chemistry, vol. 256, no. 21, pp. 11112–11116, 1981.

G. I. Belogrudov, “Recent advances in structure-functional studies of mitochondrial factor B,” Journal of Bioenergetics and Biomembranes, vol. 41, no. 2, pp. 137–143, 2009.

K. N. Alavian, H. Li, L. Collis et al., “Bcl-xL regulates metabolic efficiency of neurons through interaction with the mitochondrial F₁FO ATP synthase,” Nature Cell Biology, vol. 13, no. 10, pp. 1224–1233, 2011.

Y. B. Chen, M. A. Aon, Y. T. Hsu et al., “Bcl-xL regulates mitochondrial energetics by stabilizing the inner membrane potential,” The Journal of Cell Biology, vol. 195, no. 2, pp. 263–276, 2011.

A. Mourier, B. Ruzzenente, T. Brandt, W. Kuhlbrandt, and N. G. Larsson, “Loss of LRPPRC causes ATP synthase deficiency,” Human Molecular Genetics, vol. 23, no. 10, pp. 2580–2592, 2014.

M. S. Mai and W. S. Allison, “Inhibition of an oligomycin-sensitive ATPase by cationic dyes, some of which are atypical uncouplers of intact mitochondria,” Archives of Biochemistry and Biophysics, vol. 221, no. 2, pp. 467–476, 1983.

A. J. M. Moreno, P. I. Moreira, J. B. A. Custódio, and M. S. Santos, “Mechanism of inhibition of mitochondrial ATP synthase by 17β-estradiol,” Journal of Bioenergetics and Biomembranes, vol. 45, no. 3, pp. 261–270, 2013.

J. Zheng and V. D. Ramirez, “Purification and identification of an estrogen binding protein from rat brain: oligomycin sensitivity conferring protein (OSCP), a subunit of mitochondrial F0F1-ATP synthase/ATPase,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 68, no. 1-2, pp. 65–75, 1999.

F. Massart, S. Paolini, E. Piscitelli, M. L. Brandi, and G. Solaini, “Dose-dependent inhibition of mitochondrial ATP synthase by 17β-estradiol,” Gynecological Endocrinology, vol. 16, no. 5, pp. 373–377, 2002.

P. Turina, A. Rebecchi, M. D'Alessandro, S. Anefors, and B. A. Melandri, “Modulation of proton pumping efficiency in bacterial ATP synthases,” Biochimica et Biophysica Acta (BBA) – Bioenergetics, vol. 1757, no. 5-6, pp. 320–325, 2006.

M. D'Alessandro, P. Turina, and B. A. Melandri, “Quantitative evaluation of the intrinsic uncoupling modulated by ADP and Pi in the reconstituted ATP synthase of Escherichia coli,” Biochimica et Biophysica Acta (BBA) - Bioenergetics, vol. 1807, no. 1, pp. 130–143, 2011.

L. Nathanson and Z. Gromet-Elhanan, “Mutations in the β-subunit Thr¹⁵⁹ and Glu¹⁸⁴ of the Rhodospirillum rubrum F₀F₁ ATP synthase reveal differences in ligands for the coupled Mg²⁺- and decoupled Ca²⁺-dependent F₀F₁ activities,” Journal of Biological Chemistry, vol. 275, no. 2, pp. 901–905, 2000.

S. Papageorgiou, A. B. Melandri, and G. Solaini, “Relevance of divalent cations to ATP-driven proton pumping in beef heart mitochondrial F₀F₁-ATPase,” Journal of Bioenergetics and Biomembranes, vol. 30, no. 6, pp. 533–541, 1998.

S. Nesci, F. Trombetti, V. Ventrella, M. Pirini, and A. Pagliarani, “Kinetic properties of the mitochondrial F₁FO-ATPase activity elicited by Ca²⁺ in replacement of Mg²⁺,” Biochimie, vol. 140, pp. 73–81, 2017.

V. De Col, E. Petrussa, V. Casolo et al., “Properties of the permeability transition of pea stem mitochondria,” Frontiers in Physiology, vol. 9, article 1626, 2018.

W. C. Tucker, A. Schwarz, T. Levine et al., “Observation of calcium-dependent unidirectional rotational motion in recombinant photosynthetic F1-ATPase molecules,” Journal of Biological Chemistry, vol. 279, no. 46, pp. 47415–47418, 2004.

V. Giorgio, V. Burchell, M. Schiavone et al., “Ca²⁺ binding to F-ATP synthase β subunit triggers the mitochondrial permeability transition,” EMBO reports, vol. 18, no. 7, pp. 1065–1076, 2017.

I. Szabó and M. Zoratti, “Mitochondrial channels: ion fluxes and more,” Physiological Reviews, vol. 94, no. 2, pp. 519–608, 2014.

P. Bernardi, A. Rasola, M. Forte, and G. Lippe, “The mitochondrial permeability transition pore: channel formation by F-ATP synthase, integration in signal transduction, and role in pathophysiology,” Physiological Reviews, vol. 95, no. 4, pp. 1111–1155, 2015.

M. Carraro, V. Checchetto, G. Sartori et al., “High-conductance channel formation in yeast mitochondria is mediated by F-ATP synthase e and g subunits,” Cellular Physiology and Biochemistry, vol. 50, no. 5, pp. 1840–1855, 2018.

M. A. Neginskaya, M. E. Solesio, E. V. Berezhnaya et al., “ATP synthase C-subunit-deficient mitochondria have a small cyclosporine A-sensitive channel, but lack the permeability transition pore,” Cell Reports, vol. 26, no. 1, pp. 11–17.e2, 2019.

V. Giorgio, S. von Stockum, M. Antoniel et al., “Dimers of mitochondrial ATP synthase form the permeability transition pore,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 15, pp. 5887–5892, 2013.

S. von Stockum, V. Giorgio, E. Trevisan et al., “F-ATPase of Drosophila melanogaster forms 53-picosiemen (53-pS) channels responsible for mitochondrial Ca²⁺⁻induced Ca²⁺ release,” Journal of Biological Chemistry, vol. 290, no. 8, pp. 4537–4544, 2015.

K. N. Alavian, G. Beutner, E. Lazrove et al., “An uncoupling channel within the c-subunit ring of the F₁FO ATP synthase is the mitochondrial permeability transition pore,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 29, pp. 10580–10585, 2014.

L. Guo, M. Carraro, G. Sartori et al., “Arginine 107 of yeast ATP synthase subunit g mediates sensitivity of the mitochondrial permeability transition to phenylglyoxal,” Journal of Biological Chemistry, vol. 293, no. 38, pp. 14632–14645, 2018.

M. Antoniel, K. Jones, S. Antonucci et al., “The unique histidine in OSCP subunit of F-ATP synthase mediates inhibition of the permeability transition pore by acidic pH,” EMBO reports, vol. 19, no. 2, pp. 257–268, 2018.

V. Giorgio, E. Bisetto, M. E. Soriano et al., “Cyclophilin D modulates mitochondrial F0F1-ATP synthase by interacting with the lateral stalk of the complex,” Journal of Biological Chemistry, vol. 284, no. 49, pp. 33982–33988, 2009.

K. M. Johnson, X. Chen, A. Boitano, L. Swenson, A. W. Opipari Jr, and G. D. Glick, “Identification and validation of the mitochondrial F1F0-ATPase as the molecular target of the immunomodulatory benzodiazepine Bz-423,” Chemistry & Biology, vol. 12, no. 4, pp. 485–496, 2005.

E. Gauba, L. Guo, and H. Du, “Cyclophilin D promotes brain mitochondrial F1FO ATP synthase dysfunction in aging mice,” Journal of Alzheimer’s Disease, vol. 55, no. 4, pp. 1351–1362, 2016.

S. J. Beck, L. Guo, A. Phensy et al., “Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer’s disease,” Nature Communications, vol. 7, no. 1, article 11483, 2016.

S. Shanmughapriya, S. Rajan, N. E. Hoffman et al., “SPG7 is an essential and conserved component of the mitochondrial permeability transition pore,” Molecular Cell, vol. 60, no. 1, pp. 47–62, 2015.

Q. Long, K. Yang, and Q. Yang, “Regulation of mitochondrial ATP synthase in cardiac pathophysiology,” American Journal of Cardiovascular Disease, vol. 5, no. 1, pp. 19–32, 2015.

A. Dautant, T. Meier, A. Hahn, D. Tribouillard-Tanvier, J. P. di Rago, and R. Kucharczyk, “ATP synthase diseases of mitochondrial genetic origin,” Frontiers in Physiology, vol. 9, p. 329, 2018.

L. Formentini, A. J. Ryan, M. Gálvez-Santisteban et al., “Mitochondrial H⁺-ATP synthase in human skeletal muscle: contribution to dyslipidaemia and insulin resistance,” Diabetologia, vol. 60, no. 10, pp. 2052–2065, 2017.

L. Tran, P. R. Langlais, N. Hoffman, L. Roust, and C. S. Katsanos, “Mitochondrial ATP synthase β-subunit production rate and ATP synthase specific activity are reduced in skeletal muscle of humans with obesity,” Experimental Physiology, vol. 104, no. 1, pp. 126–135, 2019.

P. B. Esparza-Moltó and J. M. Cuezva, “The role of mitochondrial H⁺-ATP synthase in cancer,” Frontiers in Oncology, vol. 8, p. 53, 2018.

Z. Ahmad, S. S. Hassan, and S. Azim, “A therapeutic connection between dietary phytochemicals and ATP synthase,” Current Medicinal Chemistry, vol. 24, no. 35, pp. 3894–3906, 2017.

S. Hong and P. L. Pedersen, “ATP synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas,” Microbiology and Molecular Biology Reviews, vol. 72, no. 4, pp. 590–641, 2008.

A. R. Salomon, D. W. Voehringer, L. A. Herzenberg, and C. Khosla, “Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F(0)F(1)-ATPase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 26, pp. 14766–14771, 2000.

J. Goldberg, A. Currais, M. Prior et al., “The mitochondrial ATP synthase is a shared drug target for aging and dementia,” Aging Cell, vol. 17, no. 2, article e12715, 2018.

L. L. Ling, T. Schneider, A. J. Peoples et al., “A new antibiotic kills pathogens without detectable resistance,” Nature, vol. 517, no. 7535, pp. 455–459, 2015.

J. Zheng and V. D. Ramirez, “Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals,” British Journal of Pharmacology, vol. 130, no. 5, pp. 1115–1123, 2000.

J. R. Gledhill, M. G. Montgomery, A. G. W. Leslie, and J. E. Walker, “Mechanism of inhibition of bovine F₁-ATPase by resveratrol and related polyphenols,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 34, pp. 13632–13637, 2007.

J. A. Baur, K. J. Pearson, N. L. Price et al., “Resveratrol improves health and survival of mice on a high-calorie diet,” Nature, vol. 444, no. 7117, pp. 337–342, 2006.

C. Torres-Fuentes, H. Schellekens, T. G. Dinan, and J. F. Cryan, “A natural solution for obesity: bioactives for the prevention and treatment of weight gain. A review,” Nutritional Neuroscience, vol. 18, no. 2, pp. 49–65, 2015.

F. Bakkali, S. Averbeck, D. Averbeck, and M. Idaomar, “Biological effects of essential oils – a review,” Food and Chemical Toxicology, vol. 46, no. 2, pp. 446–475, 2008.

T. C. Chen, C. O. Fonseca, and A. H. Schönthal, “Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy,” American Journal of Cancer Research, vol. 5, no. 5, pp. 1580–1593, 2015.

S. S. Jia, G. P. Xi, M. Zhang et al., “Induction of apoptosis by D-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells,” Oncology Reports, vol. 29, no. 1, pp. 349–354, 2012.

J. Lone and J. W. Yun, “Monoterpene limonene induces brown fat-like phenotype in 3T3-L1 white adipocytes,” Life Sciences, vol. 153, pp. 198–206, 2016.

J. B. Custódio, M. V. Ribeiro, F. S. Silva, M. Machado, and M. C. Sousa, “The essential oils component p-cymene induces proton leak through Fo-ATP synthase and uncoupling of mitochondrial respiration,” Journal of Experimental Pharmacology, vol. 3, pp. 69–76, 2011.